In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…
Search results for: postmenopausal osteoporosis
FDA Approves New Osteoporosis Medication
Romosozumab-aqqg has been approved in the U.S. for treating postmenopausal women with osteoporosis at high risk of fracture…
A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…
Improve Your Recognition & Treatment of Osteoporosis
BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…
Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
NEW YORK (Reuters Health)—Levels of two bone markers currently recommended for evaluating postmenopausal women with osteoporosis have no association with hip fracture risk, according to a new study using Women’s Health Initiative data. “At least in these postmenopausal women, it was not a useful endeavor to check bone turnover markers to predict hip-fracture risk. That…
Circulating microRNAs May Serve as Osteoporosis Biomarkers
New research suggests circulating hsa-miR-122-5p and hsa-miR-4516 may become diagnostic biomarkers for osteoporosis. The study found the presence of these microRNAs were associated with osteoporotic fragility fractures and reduced bone mineral density…
RA Patients May Not Receive Needed Osteoporosis Screening & Treatment
New research examined the frequency of osteoporosis screening and treatment for RA patients from 2003–2014, including four years following the release of the 2010 ACR guideline on glucocorticoid-induced osteoporosis prevention and treatment. The results: Approximately half of RA patients for whom treatment was indicated never received osteoporosis medication. Researchers also found that RA patients, despite their increased risk for developing osteoporosis, were not more likely to receive osteoporosis care than OA patients…
Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…
Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal
NEW YORK (Reuters Health)—Baseline measures of bone density, microarchitecture and strength predict the risk of fragility fractures in postmenopausal women, according to results from the Calgary CaMOS cohort. Changes in bone health were not associated with fracture risk, however, said Dr. Lauren A. Burt from the University of Calgary, Canada, who worked on the study….
Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis
The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »